2024-05-16 11:30:00 ET
Summary
- Rising organ transportation competition poses a threat to Blade's Medical segment, but Q1 revenue suggests there hasn't been a material impact so far.
- TransMedics' strong logistics growth and aggressive expansion plan put Blade and TransMedics on a collision course in coming years.
- Blade's valuation is low though, and if the Medical segment continues to grow or eVTOLs expand the UAM market, the stock could perform well.
The last time I wrote about Blade ( BLDE ) I suggested that rising organ transplant transportation competition could be a threat to the company's Medical segment, which is currently driving growth and profitability. Blade's first quarter Medical revenue was strong, which seems to imply that this concern hasn't eventuated so far. TransMedics' ( TMDX ) first quarter logistics growth was extremely strong though and the company retains an aggressive expansion plan, leaving Blade and TransMedics on a crash course....
Read the full article on Seeking Alpha
For further details see:
Blade Air Mobility: No Signs Of Competition Yet